
Methotrexate
Methotrexate is prescription-only. Taken once a week, it improves rheumatoid arthritis and severe psoriasis and helps children with juvenile arthritis; it is also used in cancer chemotherapy, on different schedules. It carries a boxed warning for birth defects and fetal death, severe allergic reactions, serious toxicity to blood, liver, lungs, gut, skin and kidneys, and fatal dosing errors. Folic acid, NSAIDs and alcohol all matter with this drug.
Prescription medication: not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.
Quick decision guide
May help most
Adults with rheumatoid arthritis or severe psoriasis and children with pJIA, treated and monitored by a specialist; and people receiving it as part of a cancer regimen
Common dosing range
Set by the prescriber. Rheumatoid arthritis: the label starts at 7.5 mg once weekly and adjusts for response. Psoriasis: 10 to 25 mg once weekly, no more than 30 mg a week. pJIA: starting 10 mg/m2 once weekly. Cancer doses depend on the regimen
When to expect effects
Rheumatoid arthritis and pJIA: most responses appear 3 to 6 weeks after starting, some up to 12 weeks (label)
Watch out for
Boxed warning: can cause birth defects and fetal death, severe allergic reactions and serious, sometimes fatal, toxicity to the bone marrow, gut, liver, lungs, skin and kidneys. Taking a weekly dose every day by mistake has been fatal
What is it
Methotrexate is a prescription-only drug that blocks the use of folate in cells. At low doses taken once a week it is a mainstay treatment for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis (pJIA) and severe psoriasis; in cancer care it is part of chemotherapy for acute lymphoblastic leukemia, mycosis fungoides and some non-Hodgkin lymphomas, on schedules and doses set by an oncologist that differ from the weekly arthritis dose. It comes as tablets (Trexall and generics), oral solutions (Xatmep, Jylamvo) and self-injection pens (Otrexup, Rasuvo). For arthritis and psoriasis it is usually taken once a week, and the label warns that taking a weekly dose daily by mistake has caused deaths. People who take it often ask about folic acid, pain relievers such as ibuprofen and naproxen, and alcohol.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
rheumatoid arthritis Good Evidence | ACR50 response 15 more per 100 vs placebo at 52 weeks (risk ratio 3.0, NNT 7) | Adults with active rheumatoid arthritis under specialist care | Most responses within 3 to 6 weeks; trials ran 12 to 52 weeks |
moderate to severe plaque psoriasis Good Evidence | PASI 75 in 41 vs 10 percent with placebo at 16 weeks | Adults with moderate to severe plaque psoriasis new to methotrexate | Measured at 16 weeks |
polyarticular juvenile idiopathic arthritis (pJIA) Limited Evidence | 63 vs 36 percent improved with 10 mg/m2 weekly vs placebo | Children with juvenile rheumatoid arthritis (now called juvenile idiopathic arthritis) that had not responded to other treatment, as studied in this trial | Measured at 6 months |
rheumatoid arthritis
- Effect
- ACR50 response 15 more per 100 vs placebo at 52 weeks (risk ratio 3.0, NNT 7)
- Best fit
- Adults with active rheumatoid arthritis under specialist care
- Time
- Most responses within 3 to 6 weeks; trials ran 12 to 52 weeks
moderate to severe plaque psoriasis
- Effect
- PASI 75 in 41 vs 10 percent with placebo at 16 weeks
- Best fit
- Adults with moderate to severe plaque psoriasis new to methotrexate
- Time
- Measured at 16 weeks
polyarticular juvenile idiopathic arthritis (pJIA)
- Effect
- 63 vs 36 percent improved with 10 mg/m2 weekly vs placebo
- Best fit
- Children with juvenile rheumatoid arthritis (now called juvenile idiopathic arthritis) that had not responded to other treatment, as studied in this trial
- Time
- Measured at 6 months
Evidence for 3 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
rheumatoid arthritis
Disease adjunctA 2014 Cochrane review of 7 randomized trials (732 people who had failed earlier treatments, weekly doses of 5 to 25 mg, followed 12 to 52 weeks) found clinically important benefits. At 52 weeks, a major (ACR50) improvement was 3 times as likely as with placebo (15 more people out of 100; number needed to treat 7). Physical function and the physical part of quality of life also improved, and fewer people had worsening joint erosions on X-ray (8 fewer out of 100). Side effects were common: 16 percent stopped because of them versus 8 percent on placebo, though serious side effects did not differ significantly (3 versus 2 percent). The review rated the evidence mainly moderate to high quality. These trials were short and in people with long-standing disease.
Bottom line: Clearly improves rheumatoid arthritis symptoms and function, at the cost of frequent side effects.
moderate to severe plaque psoriasis
Disease adjunctThe METOP trial randomly assigned 120 adults with moderate to severe plaque psoriasis who had never had methotrexate to weekly injections of methotrexate (starting at 17.5 mg, up to 22.5 mg) or placebo for 16 weeks, all with folic acid 5 mg a week. At 16 weeks, 41 percent on methotrexate reached a 75 percent improvement in psoriasis score (PASI 75) versus 10 percent on placebo. No one died or had a serious infection, cancer or major heart event over 52 weeks, and 3 percent had serious adverse events. It is a single, manufacturer-funded trial of the injected form; the label approves methotrexate for severe psoriasis.
Bottom line: About 4 in 10 had major skin clearing at 16 weeks versus 1 in 10 on placebo.
polyarticular juvenile idiopathic arthritis (pJIA)
Disease adjunctA 1992 US and Soviet double-blind trial gave 127 children with resistant juvenile rheumatoid arthritis, the older name for juvenile idiopathic arthritis (mean age 10.1 years, about 5 years of disease that had not responded to other treatment) weekly oral methotrexate at 10 mg/m2, 5 mg/m2 or placebo for 6 months. On a composite response index, 63 percent improved on 10 mg/m2 versus 36 percent on placebo; the 5 mg/m2 dose (32 percent) worked no better than placebo. The higher dose also reduced painful and limited joints and inflammation markers. Three children stopped for mild to moderate side effects and none had severe toxicity in this short study. It is one older, moderate-sized trial.
Bottom line: Weekly low-dose methotrexate helped about twice as many children as placebo over 6 months.
How it works
How to take it
What to track
Bottom line: Once a week, never daily unless prescribed that way, with regular blood tests and every new supplement or pain reliever cleared with your prescriber.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Embryo-fetal toxicity (boxed warning): methotrexate can cause birth defects and fetal death, and it is contraindicated in pregnancy for non-cancer conditions.
Severe allergic reactions, including anaphylaxis (boxed warning); people with a history of severe reactions to methotrexate must not take it.
Serious, sometimes fatal, toxicity (boxed warning): severe bone marrow suppression, severe gut toxicity including bleeding and perforation, liver scarring and failure (risk higher with heavy alcohol use), lung inflammation, severe skin reactions such as Stevens-Johnson syndrome, and kidney failure. The label calls for close monitoring of these organs.
Fatal medication errors (boxed warning): deaths have occurred, most often when people took a once-weekly dose every day.
Serious and opportunistic infections (including pneumonia, fungal infections, hepatitis B reactivation, tuberculosis and shingles), nerve and brain toxicity, lymphoma and other secondary cancers, and reduced fertility. Live vaccines are not recommended during treatment.
Who should avoid it
- Pregnant women taking it for a non-cancer condition such as arthritis or psoriasis (label contraindication)
- People with a history of severe hypersensitivity to methotrexate, including anaphylaxis (label contraindication)
- People with kidney impairment or fluid build-up (such as pleural effusions or ascites) need close monitoring, because methotrexate is cleared more slowly and side effects are more likely
Pregnancy & breastfeeding
Pregnancy: methotrexate can cause birth defects and fetal death and is contraindicated in pregnancy when used for non-cancer conditions. In a prospective study cited on the label, miscarriage occurred in 42 percent of pregnancies exposed to methotrexate (30 mg a week or less) after conception, versus 22 percent in unexposed women with autoimmune disease. The label says to check pregnancy status before starting and advises effective contraception during treatment and for 6 months after the last dose for women who could become pregnant, and for 3 months after the last dose for men with female partners who could become pregnant. Breastfeeding: methotrexate passes into breast milk in low amounts, and the label says not to breastfeed during treatment and for 1 week after the last dose. Plan any pregnancy with your prescriber.
Interactions
The label lists aspirin and other NSAIDs among drugs that can raise methotrexate levels and the risk of severe side effects, such as low blood counts and kidney problems; the methotrexate injection label warns that unexpectedly severe and fatal gut toxicity has occurred mainly with high-dose methotrexate given with NSAIDs, and the methotrexate tablet label says people with reduced kidney function are at higher risk of side effects. A Cochrane review of people with rheumatoid arthritis on low-dose weekly methotrexate found NSAIDs appeared safe with appropriate monitoring, but anti-inflammatory doses of aspirin should be avoided. Do not start any NSAID, including OTC ones, without your prescriber's agreement.
The label lists oral antibiotics, penicillins, sulfonamide antibiotics and other antifolate drugs (such as dapsone and pyrimethamine) among products that can raise methotrexate levels and increase the risk of severe side effects, and says to monitor closely if they must be used together. Tell every prescriber, including urgent care and dentists, that you take methotrexate before starting an antibiotic.
The label lists proton pump inhibitors among drugs that can raise methotrexate levels and increase the risk of severe side effects, and says to monitor closely if they must be used together. Your care team decides whether any change is needed.
Nitrous oxide strengthens methotrexate's effect on folate-dependent pathways and may increase the risk of severe side effects. The label says to avoid nitrous oxide anesthesia in people taking methotrexate, so tell your dentist and surgical team that you take it.
Methotrexate can cause severe and possibly irreversible liver damage, including fibrosis, cirrhosis and fatal liver failure, and the label says this risk is increased with heavy alcohol consumption; the Otrexup and Rasuvo labels list alcoholism as a contraindication. In a UK study of 11,839 people with rheumatoid arthritis starting methotrexate, drinking more than 21 UK units a week was linked with more liver enzyme rises than not drinking; the label sets no safe amount. Tell your prescriber whether you drink and whenever the amount changes, as the Medication Guide asks, and avoid heavy drinking.
Methotrexate works against folate, and the label says folate deficiency may increase its side effects, so for rheumatoid arthritis, pJIA and psoriasis it directs folic or folinic acid. In a Cochrane review of 6 trials (624 people with rheumatoid arthritis), folate cut stomach side effects by 26 percent, liver enzyme rises by 77 percent and stopping methotrexate by 61 percent, without a significant loss of effect. In cancer treatment, folic acid products may make methotrexate less effective, and the label says to take them only as directed. Your prescriber sets the folate product, dose and day; this includes folic acid in multivitamins.
Documented interactions
Evidence-graded pair pages with sources, dosing notes, and timing guidance, a complement to the narrative section above.
Warnings (3)
+ alcohol
highMethotrexate can cause severe and possibly irreversible liver damage, including fibrosis, cirrhosis and fatal liver failure, and its label states that this risk is increased with heavy alcohol consumption; the Otrexup and Rasuvo injection labels go further and list alcoholism as a contraindication. Alcohol and methotrexate both act on the liver, so heavy drinking adds to methotrexate's own liver risk. In a UK primary-care study of 11,839 people with rheumatoid arthritis starting methotrexate, drinking more than 21 UK units a week was linked with higher rates of raised liver enzymes than not drinking; this is an association from routine records, and the label sets no safe amount of alcohol.
+ nsaids
highMethotrexate is cleared almost entirely by the kidneys. NSAIDs reduce renal blood flow by blocking prostaglandins and compete with methotrexate at renal tubular transporters, both of which slow methotrexate elimination and raise its blood levels. The danger is greatest with high-dose methotrexate (cancer chemotherapy) or pre-existing kidney impairment, where the buildup can cause bone marrow suppression, mouth and gut ulceration, liver injury, and acute kidney injury. In low-dose weekly methotrexate for autoimmune disease with healthy kidneys, the interaction is usually more modest and often manageable under prescriber supervision.
+ folate
moderateMethotrexate works by blocking the enzyme that recycles folate into its active form, which depletes folate in normal tissues and drives common side effects such as nausea, mouth sores, and raised liver enzymes. The methotrexate label says folate deficiency may increase its side effects and directs folic or folinic acid for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriasis; a Cochrane review found folate cut stomach and liver side effects in rheumatoid arthritis without a significant loss of effect. In cancer treatment, the label says products containing folic acid may make methotrexate less effective and should be taken only when directed.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Should I take folic acid with methotrexate?⌄
For rheumatoid arthritis, juvenile arthritis and psoriasis, the label directs folic or folinic acid, and a Cochrane review found it reduced stomach side effects, liver test rises and stopping treatment without a significant loss of benefit. Your prescriber sets the product, dose and day. In cancer treatment, do not take folic acid unless your oncologist directs it, because it can make methotrexate less effective.
Can I take ibuprofen or naproxen with methotrexate?⌄
Only with your prescriber's agreement. NSAIDs can raise methotrexate levels, which is most dangerous with high doses or kidney problems. Many people with rheumatoid arthritis on low-dose weekly methotrexate use NSAIDs under monitoring, but the decision is your prescriber's.
Can I drink alcohol while taking methotrexate?⌄
The label says heavy alcohol use increases the risk of liver damage from methotrexate, and its patient information asks you to tell your prescriber if you drink and if your drinking changes. Ask your prescriber what is safe for you.
Why is methotrexate taken only once a week?⌄
For arthritis and psoriasis the label sets once-weekly dosing, and it warns that people who took a weekly dose every day by mistake have died. Take it exactly as prescribed, on the same day each week, and ask your pharmacist if anything about the schedule is unclear.
Do I need blood tests on methotrexate?⌄
Yes. The label calls for blood counts, liver tests and kidney function at the start and regularly during treatment, because serious toxicity can develop without symptoms. Your prescriber sets the schedule.
References by claim
rheumatoid arthritis
Lopez-Olivo et al., 2014 · PMC (2014) link
moderate to severe plaque psoriasis
Warren et al., 2017 · PubMed (2017) link
polyarticular juvenile idiopathic arthritis (pJIA)
Giannini et al., 1992 · PubMed (1992) link
Safety
Trexall (methotrexate tablets) prescribing information · DailyMed (FDA label) link
Interaction: NSAIDs (ibuprofen, naproxen, aspirin and others)
Interaction: Folic acid and folinic acid (folate)
Shea et al., 2013 · PMC (2013) link
Track Methotrexate with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.
